Seres Therapeutics announced two key transactions: a $25 million payment from Nestlé Health Science in 2026 as a buyout of future VOWST sales milestones, and a lease restructuring that reduces annual facility costs and long-term obligations. These moves strengthen Seres' balance sheet and extend its operating cash runway into the first quarter of 2027. The company continues to advance its live biotherapeutic programs, including the Phase 2-ready SER-155, with clinical data expected soon from an investigator-sponsored study on immune checkpoint inhibitor-related enterocolitis. Seres aims to maintain financial discipline while pursuing partnerships and funding to support its pipeline development.
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
Alibaba and Baidu shares rose after Apple received approval from China's Cyberspace Administration to include Apple Intelligence, integrating Alibaba's Qwen AI model and Baidu's AI features into Apple devices in China. This partnership allows users t...
Ondo Finance has introduced the first tokenized stock representations backed by DTCC tokenized entitlements, joining major financial firms in a significant tokenization initiative. This move highlights Ondo's unique position in building infrastructur...
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
